[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

EFFECT

Rhea-AI Filing Summary

Analyzing...

11/24/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	November 21, 2025

Accession Number:

0001214659-25-016826

Submission Type:

POS AM

CIK:	0001643918
Company Name:	Biodexa Pharmaceuticals Plc
File Number:	333-278040

Source: View Original Filing on SEC EDGAR

Biodexa Pharmaceuticals plc

NASDAQ:BDRX

View BDRX Stock Overview →

BDRX Rankings

#7045 Ranked by Market Cap

N/A Ranked by Dividends

BDRX Latest News

Mar 9, 2026

Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Feb 19, 2026

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Feb 4, 2026

Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Jan 5, 2026

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Dec 18, 2025

Biodexa Announces Pricing of $10 Million Public Offering

BDRX Latest SEC Filings

Feb 17, 2026

[SCHEDULE 13G] Biodexa Pharmaceuticals Plc Passive Investment Disclosure (>5%)

Feb 4, 2026

[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3)

Feb 4, 2026

[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3)

Feb 4, 2026

[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3)

Feb 4, 2026

[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3)

BDRX Stock Data

Market Cap 727.14k

Float 836.35k

Industry Biotechnology

Sector Healthcare

Website Link

Country United Kingdom

City Cardiff